Recently, the Delaware Chancery Court and the Third Circuit issued three significant decisions on key issues affecting licensing and M&A transactions in the life sciences industry....more
9/16/2024
/ Acquisitions ,
Breach of Contract ,
Commercially Reasonable Efforts ,
Due Diligence ,
Earn-Outs ,
IP License ,
Johnson & Johnson ,
Life Sciences ,
Medical Devices ,
Mergers ,
Patents ,
Pharmaceutical Industry ,
Royalties ,
Shareholders
On Friday, June 23, 2023, Judge Jed Rakoff issued a highly anticipated decision, permanently enjoining artist Mason Rothschild from selling “MetaBirkin” NFTs, which depict furry, digital versions of the Hermès signature...more
6/29/2023
/ Artistic Works ,
Corporate Counsel ,
Cybersquatting ,
Dilution ,
Fashion Industry ,
First Amendment ,
Likelihood of Confusion ,
Non-Fungible Tokens (NFTs) ,
Permanent Injunctions ,
Rogers Test ,
Trademark Infringement ,
Trademarks
On February 23, 2023, the European Medicines Agency (EMA) adopted a positive opinion for BEKEMV®. BEKEMV® is a biosimilar candidate referencing Alexion’s biological product SOLIRIS® (eculizumab), which is a recombinant...more
Intellectual property protection is more important than ever in the beauty industry as the market for cosmetics becomes more crowded and competitive.
Some cosmetic companies have used patents as a key tool to...more
Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab) and HANQUYOU...more
In 2021, the FDA’s Purple Book went live, providing a searchable database of licensed biological products, including the patent information provided to biosimilar applicants during the patent dance. Pursuant to a law enacted...more
According to various reports, Celltrion has received approval from Health Canada for YUFLYMA, a biosimilar of AbbVie’s HUMIRA product. YUFLYMA was previously approved in Europe, and is a high-concentration, low-volume,...more
As we close out another calendar year, we look back at the top legal developments of 2021 that could influence the market for biologics and biosimilars. There were many interesting decisions and other developments in district...more
12/28/2021
/ AbbVie ,
Antitrust Litigation ,
Biosimilars ,
Fresenius ,
Generic Drugs ,
International Trade Commission (ITC) ,
Johnson & Johnson ,
Mylan Pharmaceuticals ,
Orange Book ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pfizer ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Prescription Drugs ,
Proposed Legislation ,
Sanofi ,
Sherman Act ,
The Clayton Act
Last week, results of Tanvex’s phase III study on its trastuzumab biosimilar candidate (TX05) were published in connection with the European Society for Medical Oncology’s (ESMO’s) Congress 2021. The study compared the...more
Last week, Enzene Biosciences announced that it has received marketing authorization from the Drug Controller General of India (DCGI) for its biosimilar product romiplostim. The product will be offered in three dosage...more
The domestic industry requirement at the U.S. International Trade Commission (ITC or Commission) continued to evolve in three significant opinions in 2014. In one opinion, the Commission set forth a nexus requirement for...more